Crimean-Congo Hemorrhagic Fever

Kazancıoğlu, Sümeyye; Akıncı, Esragül; Bodur, Hürrem

doi:10.4274/mjima.2017.12

Cited by 1 publication

(1 citation statement)

References 85 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…After dengue fever, Crimean-Congo Hemorrhagic Fever (CCHF) is the second most common viral hemorrhagic fever and the world's most widely transmitted tick-borne viral disease 1 . It's characterised by high fever, headache, weakness, nausea, vomiting, and diarrhoea, as well as elevated liver enzymes, elevated levels of creatine phosphokinase (CPK), and lactate dehydrogenase (LDH), and disturbed haemostasis 2 . Despite presentation as a low fever in the majority of cases, some patients develop severe hemorrhagic disease 3 .…”

Section: Introductionmentioning

confidence: 99%

In silico design and analyses of a multi-epitope vaccine against Crimean-Congo hemorrhagic fever virus through reverse vaccinology and immunoinformatics approaches

Omoniyi

Adebisi

Musa

et al. 2022

Sci Rep

View full text Add to dashboard Cite

Crimean Congo Hemorrhagic Fever virus (CCHFV) is a deadly human pathogen that causes an emerging zoonotic disease with a broad geographic spread, especially in Africa, Asia, and Europe, and the second most common viral hemorrhagic fever and widely transmitted tick-borne viral disease. Following infection, the patients are presented with a variety of clinical manifestations and a fatality rate of 40%. Despite the high fatality rate, there are unmet clinical interventions, as no antiviral drugs or vaccines for CCHF have been approved. Immunoinformatics pipeline and reverse vaccinology were used in this study to design a multi-epitope vaccine that may elicit a protective humoral and cellular immune response against Crimean-Congo hemorrhagic fever virus infection. Three essential virulent and antigenic proteins (S, M, and L) were used to predict seven CTL and 18 HTL epitopes that were non-allergenic, antigenic, IFN-γ inducing, and non-toxic. The epitopes were connected using linkers and 50S ribosomal protein L7/L12 was used as an adjuvant and raised a multi-epitope vaccine (MEV) that is 567 amino acids long. Molecular docking and simulation of the predicted 3D structure of the MEV with the toll-like (TLR2, TLR3, and TLR4) receptors and major histocompatibility complex (MCH-I and MCH-II) indicate high interactions and stability of the complexes, MM-GBSA free binding energy calculation revealed a favourable protein–protein complex. Maximum MEV expression was achieved with a CAI value of 0.98 through in silico cloning in the Drosophila melanogaster host. According to the immune simulation, IgG1, T-helper cells, T-cytotoxic cells, INF-γ, and IL-2 were predicted to be significantly elevated. These robust computational analyses demonstrated that the proposed MEV is effective in preventing CCHFV infections. However, it is still necessary to conduct both in vitro and in vivo experiments to validate the potential of the vaccine.

show abstract

Section: Introductionmentioning

confidence: 99%